Healthcare Stocks are Coming Back with the XLV up 6.83% MTD, what’s Going on?

HEALTHCARE Stocks Are Coming Back Led by Biopharma so what’s next? The XLV portfolio weighting has shifted  to LargeCap Biopharma which has performed well (see our articles). Biotech has shown strong momentum in Q3 with SMID caps leading: IBB up 16.3% YTD and...

With the Healthcare Sector in Turmoil Should You Rebalance Your Portfolio? Update-3…C’mon Back Biotech at ASCO!

Update-3 5/22-23….. 10:50a EDT….VIGL  continues to run on Sanofi acquisition.at $8/sh. Should spark our SMID biotech trading list but XBI is stuck at $78. Ahead of ASCO we should see more green shoots among SMID biotechs and soon some major news from...

Bear Market Rally Spurs Biotech Stocks: A Primer on Tariffs…Update-3…Pivot Day Confirmed

Update-3 …ABBVIE (ABBV) beat with adj. EPS 2.46 earnings and revenues of $13.343B  an increase of 4%, but tariff issues lurking,,, I$10M investments will be made in U.S. Strong sales $6.264B of new immunology drugs Rinvoq and Skirizi an increase of 16.6%.  EPS...

Biotech and MedTech Portfolio Notes on a FED Day…Update 4… 2/15 Small cap rally continues

Update-4. 2/15….2:30p EST XBI pushing for new 52 weeks highs at $93.61. Biotechs/medtechs strong: CRBU, CRMD, CRSP, CPRX, CYRX, ILMN,SUPN, TWST, VCEL. Update-3 2/6..3P EST Some of my SMID caps are coming alive as the XBI ticks up to $89 level: strength among my...

Pin It on Pinterest